We report the molecular characterization of 8 primary gastric carcinomas, corresponding xenografts, and 2 novel gastric carcinoma cell lines. We compared the tumors and cell lines, with respect to histology, immunohistochemistry, copy number, and hypermethylation of up to 38 genes using methylation-specific multiplex ligation-dependent probe amplification, and TP53 and CDH1 mutation analysis where relevant. The primary tumors and xenografts were histologically comparable and shared expression of 11 of 14 immunohistochemical markers (E-cadherin, beta-catenin, COX-2, p53, p16, TFF1, cyclin E, MLH1, SMAD4, p27, KLK3, CASR, CHFR, and DAPK1). Gains of CASR, DAPK1, and KLK3--not yet described in gastric cancer--were present in the primary tumors,...
To explore DNA methylation differences between gastric carcinoma (GC) and its corresponding cutting ...
In this study, we examined aberrant methylation of the E-cadherin, estrogen receptor, RB1, p16, p15,...
Gastric cancer, a highly heterogeneous disease, is the second leading cause of cancer death and the ...
Gastric cancer is constituted by two histomorphological entities ''intestinal'' and ''diffuse'' that...
Gastric cancer is constituted by two histomorphological entities ''intestinal'' and ''diffuse'' that...
AbstractRecent development of personal sequencers for extensive mutation analysis and bead array tec...
Gastric cancer develops through the accumulation of multiple genetic lesions that involve oncogenes,...
BACKGROUND. Transcriptional silencing by CpG-island hypermethylation now is believed to be an import...
Although the advancement of molecular oncology in gastric cancer lags behind that of colorectal canc...
Gastric cancer is the world's third leading cause of cancer mortality. In spite of significant thera...
Gastric cancer (GC) is a complex disease with heterogeneous genetic mechanisms. Genomic mutational p...
Gastric carcinogenesis is a multistep process involving alterations in oncogenes, tumour suppressor ...
BACKGROUND: Gastric "crawling-type" adenocarcinoma (CRA) is a tumor histologically characterized by ...
Gastric cancer is a result from the combination of environmental factors and an accumulation of spec...
PURPOSE: In gastric adenocarcinoma (GC), the major tumor suppressor genes (TSGs) such as p16, PTEN, ...
To explore DNA methylation differences between gastric carcinoma (GC) and its corresponding cutting ...
In this study, we examined aberrant methylation of the E-cadherin, estrogen receptor, RB1, p16, p15,...
Gastric cancer, a highly heterogeneous disease, is the second leading cause of cancer death and the ...
Gastric cancer is constituted by two histomorphological entities ''intestinal'' and ''diffuse'' that...
Gastric cancer is constituted by two histomorphological entities ''intestinal'' and ''diffuse'' that...
AbstractRecent development of personal sequencers for extensive mutation analysis and bead array tec...
Gastric cancer develops through the accumulation of multiple genetic lesions that involve oncogenes,...
BACKGROUND. Transcriptional silencing by CpG-island hypermethylation now is believed to be an import...
Although the advancement of molecular oncology in gastric cancer lags behind that of colorectal canc...
Gastric cancer is the world's third leading cause of cancer mortality. In spite of significant thera...
Gastric cancer (GC) is a complex disease with heterogeneous genetic mechanisms. Genomic mutational p...
Gastric carcinogenesis is a multistep process involving alterations in oncogenes, tumour suppressor ...
BACKGROUND: Gastric "crawling-type" adenocarcinoma (CRA) is a tumor histologically characterized by ...
Gastric cancer is a result from the combination of environmental factors and an accumulation of spec...
PURPOSE: In gastric adenocarcinoma (GC), the major tumor suppressor genes (TSGs) such as p16, PTEN, ...
To explore DNA methylation differences between gastric carcinoma (GC) and its corresponding cutting ...
In this study, we examined aberrant methylation of the E-cadherin, estrogen receptor, RB1, p16, p15,...
Gastric cancer, a highly heterogeneous disease, is the second leading cause of cancer death and the ...